Chronic pain affects more than 20% of the UK population. Neurotrophic factors have been identified as therapeutic targets to improve current treatments of chronic pain. This review article focuses on nerve growth factor (NGF) and interleukin-6 (IL-6) as potential therapeutic targets. In this review we highlight the mechanisms of action and the current progress of targeted therapies in clinical trials.
Introduction
Chronic pain remains an area of considerable unmet medical need, as multiple statistics attest. For instance 6-8% of people in the UK are believed to suffer from neuropathic pain alone (Hall et al., 2013; Bouhassira et al., 2008) . For all types of chronic pain, estimates of prevalence have risen to 20% (van Hecke et al., 2013; Breivik et al., 2006) . Critically, existing treatments for these pain states are limited with more than half of patients getting inadequate relief. The costs of all this persistent pain are enormous and relate not only to the suffering of the affected individuals, but often extend to their family and colleagues. The societal costs are conservatively estimated to amount to more than $80 billion annually in the US (The National Academies Press, 2011). This rather bleak situation is not without hope. In the last decades our understanding of the neurobiological mechanisms of chronic pain have advanced considerably. This new understanding is now beginning to be translated into therapy with a spate of positive phase II or III drug trials Neurobiology of Disease 97 (2017) 127-138 
